CytoDyn Inc Sustainability Reports
CytoDyn Inc. is a clinical-stage biotechnology company focused on the clinical development of innovative treatments for multiple therapeutic indications. Its primary candidate is leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5.
Sector: Manufacturing
Country: United States
Exchange: OTC Markets
LEI: 529900Q4JAVBX3H8RF98
FIGI: BBG001SJT254
3 reports from 2014 to 2021
